Status:
COMPLETED
Propofol Cardioprotection for Type II Diabetics
Lead Sponsor:
University of British Columbia
Collaborating Sponsors:
Canadian Institutes of Health Research (CIHR)
Conditions:
Myocardial Injury
Eligibility:
All Genders
19-29 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to determine if an intravenous anesthetic with antioxidant properties will protect the heart of diabetic patients from injury while undergoing coronary bypass surgery.
Detailed Description
Diabetic patients are at elevated risk for low cardiac output syndrome. This high risk scenario adversely affects up to 26% of patients recovering from cardiac surgery. Aggressive hemodynamic treatmen...
Eligibility Criteria
Inclusion
- Patients with and without Type II Diabetes Mellitus
- Hemodynamically Stable
- Non urgent Coronary Bypass Grafting utilizing Cardiopulmonary Bypass
Exclusion
- Age less than 18 or greater than 80 years of age
- refuse informed consent
- Co-existing valvular heart disease
- Acute or evolving myocardial infarction
- hypersensitivity to propofol or formulation component
- Use of NSAIDs, Vitamins C or E within 5 to 7 days of surgery
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
137 Patients enrolled
Trial Details
Trial ID
NCT00734383
Start Date
April 1 2005
End Date
June 1 2012
Last Update
July 13 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UBC Dept of Anesthesiology, Pharmacology & Therapeutics, Vancouver Acute Hospital
Vancouver, British Columbia, Canada, V5Z 4E3